Matches in SemOpenAlex for { <https://semopenalex.org/work/W4250649737> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W4250649737 endingPage "51" @default.
- W4250649737 startingPage "51" @default.
- W4250649737 abstract "Aim: To evaluate the patterns of use of the out-of-hospital endocrine therapies for breast cancer in Albania during the period 2004-2014. Methods: The study was retrospective and we analyzed the prescription and consumption of these drug classes in the primary health care in Albania during 2004-2014. All data were collected from Health Insurance Institute (HII)(1) and analysed reflecting the ambulatory and outpatient use for the period 2004-2014. The data about the consumption of drugs were expressed as a number of Defined Daily Dose (DDDs) /1000 inhabitants/day. Utilization was measured in DDD/1000 inhabitants/day and was also compared with breast cancer morbidity/1000 inhabitants, to understand the covering of the population from the reimbursement scheme. For all the period under study 2004-2014, there were collected and analysed the data of import and domestic production of drugs, which altogether represent the real consumption of drugs in the country. These data were subsequently included in a comparative analysis with the utilization data according to the HII. Results: The drug with the highest values of consumption is Letrozole 0.05-0.37 DDD/1000 inhabitants/day2004-2014). Anastrazole was introduced to the scheme in 2008. Its consumption in2014 was 0.26 DDD/1000 inhabitants/day. The consumtion of Tamoxifen is reduced through these years with values 0.32-0.17 DDD/1000 inhabitants/day respectively 2004-2014. Breast cancer morbidity data indicate that there does exist a correlation statistically significant between this disease and the trend of consumption of endocrine therapies drugs (p = 0,0009) Conclusions: It is evident that a non-small part of the patients remain untreated under the scheme. There is noted a shift in use of endocrine therapy from tamoxifen to aromatase inhibitors. This trend is consistent with major international clinical guidelines that recomend preferential use of aromatase inhibitors in post-menopausal women." @default.
- W4250649737 created "2022-05-12" @default.
- W4250649737 creator A5035717078 @default.
- W4250649737 creator A5045938678 @default.
- W4250649737 date "2016-08-30" @default.
- W4250649737 modified "2023-09-26" @default.
- W4250649737 title "Utilization Trends of Endocrine Therapies for Breast Cancer in Albania During 2004-2014" @default.
- W4250649737 doi "https://doi.org/10.26417/ejis.v2i3.p51-56" @default.
- W4250649737 hasPublicationYear "2016" @default.
- W4250649737 type Work @default.
- W4250649737 citedByCount "0" @default.
- W4250649737 crossrefType "journal-article" @default.
- W4250649737 hasAuthorship W4250649737A5035717078 @default.
- W4250649737 hasAuthorship W4250649737A5045938678 @default.
- W4250649737 hasBestOaLocation W42506497372 @default.
- W4250649737 hasConcept C121608353 @default.
- W4250649737 hasConcept C126322002 @default.
- W4250649737 hasConcept C144024400 @default.
- W4250649737 hasConcept C149923435 @default.
- W4250649737 hasConcept C160735492 @default.
- W4250649737 hasConcept C162324750 @default.
- W4250649737 hasConcept C2426938 @default.
- W4250649737 hasConcept C2776865356 @default.
- W4250649737 hasConcept C2777176818 @default.
- W4250649737 hasConcept C2779703844 @default.
- W4250649737 hasConcept C2908647359 @default.
- W4250649737 hasConcept C29456083 @default.
- W4250649737 hasConcept C30772137 @default.
- W4250649737 hasConcept C36289849 @default.
- W4250649737 hasConcept C50522688 @default.
- W4250649737 hasConcept C530470458 @default.
- W4250649737 hasConcept C71924100 @default.
- W4250649737 hasConcept C98274493 @default.
- W4250649737 hasConcept C99454951 @default.
- W4250649737 hasConceptScore W4250649737C121608353 @default.
- W4250649737 hasConceptScore W4250649737C126322002 @default.
- W4250649737 hasConceptScore W4250649737C144024400 @default.
- W4250649737 hasConceptScore W4250649737C149923435 @default.
- W4250649737 hasConceptScore W4250649737C160735492 @default.
- W4250649737 hasConceptScore W4250649737C162324750 @default.
- W4250649737 hasConceptScore W4250649737C2426938 @default.
- W4250649737 hasConceptScore W4250649737C2776865356 @default.
- W4250649737 hasConceptScore W4250649737C2777176818 @default.
- W4250649737 hasConceptScore W4250649737C2779703844 @default.
- W4250649737 hasConceptScore W4250649737C2908647359 @default.
- W4250649737 hasConceptScore W4250649737C29456083 @default.
- W4250649737 hasConceptScore W4250649737C30772137 @default.
- W4250649737 hasConceptScore W4250649737C36289849 @default.
- W4250649737 hasConceptScore W4250649737C50522688 @default.
- W4250649737 hasConceptScore W4250649737C530470458 @default.
- W4250649737 hasConceptScore W4250649737C71924100 @default.
- W4250649737 hasConceptScore W4250649737C98274493 @default.
- W4250649737 hasConceptScore W4250649737C99454951 @default.
- W4250649737 hasIssue "3" @default.
- W4250649737 hasLocation W42506497371 @default.
- W4250649737 hasLocation W42506497372 @default.
- W4250649737 hasLocation W42506497373 @default.
- W4250649737 hasOpenAccess W4250649737 @default.
- W4250649737 hasPrimaryLocation W42506497371 @default.
- W4250649737 hasRelatedWork W1963742939 @default.
- W4250649737 hasRelatedWork W1997402220 @default.
- W4250649737 hasRelatedWork W2071575348 @default.
- W4250649737 hasRelatedWork W2106308465 @default.
- W4250649737 hasRelatedWork W2121619948 @default.
- W4250649737 hasRelatedWork W2162865602 @default.
- W4250649737 hasRelatedWork W2191730108 @default.
- W4250649737 hasRelatedWork W3009141905 @default.
- W4250649737 hasRelatedWork W4252040781 @default.
- W4250649737 hasRelatedWork W2519764742 @default.
- W4250649737 hasVolume "2" @default.
- W4250649737 isParatext "false" @default.
- W4250649737 isRetracted "false" @default.
- W4250649737 workType "article" @default.